Gabapentin enacarbil (XP13512/GSK1838262) as an alternative treatment to dopaminergic agents for restless legs syndrome

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.11, Iss.11, 2010-08, pp. : 1925-1932

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

XP 13512, a prodrug of gabapentin, provides clinical benefit in restless legs syndrome (RLS)

Inpharma, Vol. 1, Iss. 1471, 2005-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Gabapentin enacarbil has restless legs syndrome up in arms

Inpharma, Vol. 1, Iss. 1649, 2008-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Improve symptoms of restless legs syndrome with dopaminergic agents and other treatment options

By Adis International Limited

Drugs & Therapy Perspectives, Vol. 25, Iss. 5, 2009-05 ,pp. : 9-12

Adis International

Access to resources Recommend Favorite

Dose Response of Gabapentin Enacarbil versus Placebo in Subjects with Moderate-to-Severe Primary Restless Legs Syndrome: An Integrated Analysis of Three 12-Week Studies

By VanMeter Susan A.

CNS Drugs, Vol. 26, Iss. 9, 2012-09 ,pp. : 773-780

Adis International

Access to resources Recommend Favorite

Gabapentin is effective in treating restless legs syndrome

Inpharma, Vol. 1, Iss. 1300, 2001-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite